The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Galliamov M.G.

Fakul'tet fundamental'noĭ meditsiny MGU im. M.V. Lomonosova

Saginova E.A.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Severova M.M.

Pervyĭ MGMU im. I.M. Sechenova Minzdrava Rossii, Moskva

Samokhodskaia L.M.

Fakul'tet fundamental'noĭ meditsiny MGU im. M.V. Lomonosova

Krasnova T.N.

Fakul'tet fundamental'noĭ meditsiny MGU im. M.V. Lomonosova

Sholomova V.I.

Fakul'tet fundamental'noĭ meditsiny MGU im. M.V. Lomonosova

Sorokin Iu.D.

Klinika nefrologii, vnutrennikh i professional'nykh zabolevaniĭ, Universitetskaia klinicheskaia bol'nitsa #3 Pervogo MGMU im. I.M. Sechenova, Moskva

Mukhin N.A.

GBOU VPO «Pervyj Moskovskij gosudarstvennyj meditsinskij universitet im. I.M. Sechenova», Moskva

Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity

Authors:

Galliamov M.G., Saginova E.A., Severova M.M., Samokhodskaia L.M., Krasnova T.N., Sholomova V.I., Sorokin Iu.D., Mukhin N.A.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 31‑37

Read: 1929 times


To cite this article:

Galliamov MG, Saginova EA, Severova MM, et al. . Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity. Therapeutic Archive. 2013;85(6):31‑37. (In Russ.)

Recommended articles:
Pote­ntial for the use of nutraceuticals for hype­rlipidemia correction. Russian Journal of Preventive Medi­cine. 2025;(3):40-45
Increased expression of circular RNA circSPARC and circTMEM181 in coro­nary athe­rosclerosis. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(1):24-29
Dietary restrictions as a risk factor for binge eating diso­rder. Russian Journal of Preventive Medi­cine. 2025;(4):123-129
Obesity in the context of the «old friends» hypo­thesis. Russian Journal of Preventive Medi­cine. 2025;(4):136-141

References:

  1. Mukhin N.A., Fomin V.V., Saginova E.A. i dr. Endotelial'naya disfunktsiya i porazhenie pochek pri ozhirenii. Vestn RAMN 2006; 12: 25-31.
  2. Tanner R.M., Brown T.M., Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep 2012; 14 (2): 152-159.
  3. Zhloba A.A. Asimmetrichnyi dimetilarginin v kachestve mediatora i markera razvitii endotelial'noi disfunktsii. Arterial'naya gipertenziya. 2007; 2: 119-127.
  4. Kielstein J.T., Zoccali C. Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2008; 17 (6): 609-615.
  5. Dayal S., Lentz S.R. ADMA and hyperhomocysteinemia. Vasc Med 2005; 10: S27-33.
  6. Komitet ekspertov VNOK. Diagnostika i lechenie metabolicheskogo sindroma. Rossiiskie rekomendatsii. M 2009.
  7. Komitet ekspertov RMOAG/VNOK. Diagnostika i lechenie arterial'noi gipertenzii. (Rekomendatsii Rossiiskogo meditsinskogo obshchestva po arterial'noi gipertonii i Vserossiiskogo nauchnogo obshchestva kardiologov). Sistemnye gipertenzii 2010; 3: 5-26.
  8. Smirnov A.V., Dobronravov V.A., Kayukov I.G. Puti modernizatsii klassifikatsii khronicheskoi bolezni pochek. Klin nefrol 2010; 3: 19-23.
  9. Rudenko T.E., Kutyrina I.M. Ozhirenie kak faktor sosudistogo remodelirovaniya. Klin nefrol 2010; 3: 62-65.
  10. Agewall S., Björn F. Microalbuminuria and intima-media thickness of the carotid artery in clinically healthy men. Atherosclerosis 2002; 164 (1): 161-166.
  11. McDonald S.P., Maguire G.P., Duarte N. et al. Carotid intima-media thickness, cardiovascular risk factors and albuminuria in a remote Australian Aboriginal community. Atherosclerosis 2004; 177 (2): 423-431.
  12. Huang Y., Chen Y., Xu M. et al. Low-grade albuminuria is associated with carotid intima-media thickness in Chinese type 2 diabetic patients. J Clin Endocrinol Metab 2010; 95 (11): 5122-5128.
  13. Thomas G., Sehgal A.R., Kashyap S.R. et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6 (10): 2364-2373.
  14. Paiva H., Lehtimäki T., Laakso J. et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52 (3): 303-307.
  15. Lücke T., Kanzelmeyer N., Chobanyan K. et al. Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2008; 23 (2): 734-740.
  16. Lo J.C., Go A.S., Chandra M. et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis 2007; 50 (4): 552-558.
  17. Celik M., Iyisoy A., Celik T. et al. The relationship between L-arginine/ADMA ratio and coronary collateral development in patients with low glomerular filtration rate. Cardiol J 2012; 19 (1): 29-35.
  18. Fujii H., Takiuchi S., Kawano Y., Fukagawa M. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens 2008; 21 (6): 650-656.
  19. Mukhin N.A., Fomin V.V., Lebedeva M.V. Giperurikemiya kak komponent kardiorenal'nogo sindroma. Ter arkh 2011; 6: 5-13.
  20. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008; 359 (17): 1811-1821.
  21. Tapia E., Cristobal M., Garcia-Arroyo F.E. et al. Synergistic effect of uricase blockade plus physiologic amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. Am J Physiol Renal Physiol. 2013; [Epub ahead of print].
  22. Mazzali M., Kanbay M., Segal M.S. et al. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 2010; 12 (2): 108-117.
  23. Feig D.I. Hyperuricemia and hypertension. Adv Chronic Kidney Dis 2012; 19 (6): 377-385.
  24. Chazova I.E., Litvin A.Yu. Sindrom obstruktivnogo apnoe vo vremya sna: mekhanizmy vozniknoveniya, klinicheskoe znachenie, svyaz' s serdechno-sosudistymi zabolevaniyami, printsipy lecheniya. Kardiologicheskii vestnik 2009; 2: 89-103.
  25. Adeseun G.A., Rosas S.E. The impact of obstructive sleep apnea on chronic kidney disease. Curr Hypertens Rep 2010; 12 (5): 378-383.
  26. Fleischmann G., Fillafer G., Matterer H. et al. Prevalence of chronic kidney disease in patients with suspected sleep apnoea. Nephrol Dial Transplant 2010; 25 (1): 181-186.
  27. Bradley T.D., Floras J.S. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009; 373 (9657): 82-93.
  28. Sakaguchi Y. Shoji T., Kawabata H. et al. High Prevalence of Obstructive Sleep Apnea and Its Association with Renal Function among Nondialysis Chronic Kidney Disease Patients in Japan: A Cross-Sectional Study. Clin J Am Soc Nephrol 2011; 6 (5): 995-1000.
  29. Katz S.D., Hryniewiez K., Hriljac I. et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005; 111: 310-314.
  30. Kutyrina I.M., Mukhin N.A., Moiseev S.V. i dr. Endotelial'naya disfunktsiya i porazhenie pochek pri ozhirenii. Vestn RAMN 2006; 12: 25-31.
  31. Samokhodskaya L.M., Andreenko E.Yu., Balatskii A.V. i dr. Opredelenie individual'nogo geneticheskogo riska v razvitii serdechno-sosudistykh zabolevanii. Metod. posob. po molekulyarnoi genetike. Pod red. V.A. Tkachuka. M: Izd-vo Mosk. Un-ta 2010; 80.
  32. Tkachuk V.A. Molekulyarno-geneticheskii analiz predraspolozhennosti cheloveka k mul'tifaktorial'nym zabolevaniyam. M: Izd-vo Mosk. Un-ta 2011; 388.
  33. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 2006; 24 (4): 611-619.
  34. Fard A., Tuck C.H., Donis J.A. et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20 (9): 2039-2044.
  35. Krzyzanowska K., Mittermayer F., Kopp H.P. et al. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89 (12): 6277-6281.
  36. Eid H.M., Eritsland J., Larsen J. et al. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166 (2): 279-284.
  37. McLaughlin T., Stühlinger M., Lamendola C. et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006; 91 (5): 1896-1900.
  38. Fliser D., Kronenberg F., Kielstein J.T. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16 (8): 2456-2461.
  39. Caglar K., Yilmaz M.I., Sonmez A. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 2006; 70 (4): 781-787.
  40. Graham M., Daly L., Refsum H. et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA 1997; 277 (22): 1775-1781.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.